Creative Planning raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,033 shares of the medical instruments supplier’s stock after buying an additional 413 shares during the period. Creative Planning’s holdings in Becton, Dickinson and were worth $5,274,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of BDX. Crestwood Advisors Group LLC acquired a new position in shares of Becton, Dickinson and during the first quarter valued at approximately $101,000. North Star Investment Management Corp. increased its position in shares of Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares in the last quarter. Almanack Investment Partners LLC. acquired a new position in shares of Becton, Dickinson and during the first quarter valued at approximately $105,000. Parkside Financial Bank & Trust increased its position in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares in the last quarter. Finally, Financial Architects Inc increased its position in shares of Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock valued at $124,000 after buying an additional 261 shares in the last quarter. Institutional investors own 87.41% of the company’s stock.

Shares of Becton, Dickinson and Company (BDX) traded down 0.61% during trading on Wednesday, reaching $197.69. The company’s stock had a trading volume of 292,894 shares. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63. The stock has a 50-day moving average of $200.05 and a 200-day moving average of $189.42. The stock has a market cap of $44.99 billion, a P/E ratio of 57.25 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. Becton, Dickinson and’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.35 EPS. Analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 1.47%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

COPYRIGHT VIOLATION WARNING: “Becton, Dickinson and Company (BDX) Shares Bought by Creative Planning” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/30/becton-dickinson-and-company-bdx-shares-bought-by-creative-planning.html.

BDX has been the subject of several research analyst reports. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Bank of America Corporation reiterated a “buy” rating and set a $225.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research note on Monday, July 17th. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Cowen and Company reiterated a “buy” rating and set a $230.00 target price on shares of Becton, Dickinson and in a research note on Monday, August 14th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $195.79.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the sale, the insider now directly owns 12,861 shares in the company, valued at approximately $2,538,890.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ribo Alberto Mas sold 7,463 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the sale, the executive vice president now owns 29,323 shares in the company, valued at $5,905,945.43. The disclosure for this sale can be found here. Insiders sold a total of 48,605 shares of company stock valued at $9,718,986 in the last ninety days. 1.40% of the stock is currently owned by insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.